Publicacions en col·laboració amb investigadors/es de Universidad de Salamanca (32)

2024

  1. Fibroblast-Derived Lysyl Oxidase Increases Oxidative Phosphorylation and Stemness in Cholangiocarcinoma

    Gastroenterology, Vol. 166, Núm. 5, pp. 886-901.e7

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108

2022

  1. Beneficial effect of ursodeoxycholic acid in patients with acyl-CoA oxidase 2 (ACOX2) deficiency–associated hypertransaminasemia

    Hepatology, Vol. 76, Núm. 5, pp. 1259-1274

  2. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  3. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

  4. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation

    Journal of Hepatology, Vol. 77, Núm. 4, pp. 991-1004

  5. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

2021

  1. Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

    Cell Death and Disease, Vol. 12, Núm. 6

  2. Synthetic Conjugates of Ursodeoxycholic Acid Inhibit Cystogenesis in Experimental Models of Polycystic Liver Disease

    Hepatology, Vol. 73, Núm. 1, pp. 186-203

  3. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma: Diagnosis of NAFLD-HCC utilising serum lipidomics

    EBioMedicine, Vol. 73

2020

  1. A novel serum metabolomic profile for the differential diagnosis of distal cholangiocarcinoma and pancreatic ductal adenocarcinoma

    Cancers, Vol. 12, Núm. 6

  2. Cholangiocarcinoma 2020: the next horizon in mechanisms and management

    Nature Reviews Gastroenterology and Hepatology, Vol. 17, Núm. 9, pp. 557-588

  3. Sensitizing gastric adenocarcinoma to chemotherapy by pharmacological manipulation of drug transporters

    Biochemical Pharmacology, Vol. 171

2019

  1. Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis

    Hepatology, Vol. 70, Núm. 2, pp. 547-562

  2. Wnt–β-catenin signalling in liver development, health and disease

    Nature Reviews Gastroenterology and Hepatology, Vol. 16, Núm. 2, pp. 121-136

2018

  1. Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1335-1344

  2. MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation

    Hepatology, Vol. 67, Núm. 4, pp. 1420-1440

  3. The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1468-1477

2017

  1. Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment

    Digestive Diseases, Vol. 35, Núm. 3, pp. 275-281